Angiotensin-converting enzyme gene I/D polymorphism and renal disease

Journal of Molecular Medicine

Volumn 77, Issue 11, 1999, Pages 781-791

  Navis, Gerjan ^a   Van Der Kleij, Frank G H ^a   De Zeeuw, Dick ^a   De Jong, Paul E ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE I D polymorphism; ACE inhibitors; Genetic polymorphism; Progressive renal disease; Renal disease

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; KIDNEY DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0033378055     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001099900063     Document Type: Review

References (125)

1. 1. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165
2. 2. Klouda PT, Manos J, Acheson EJ, Dyer PA, Goldby FS, Harris R, Lawler W, Mallick NP, Williams G (1979) Strong association between idiopathic membranous glomerulopathy and HLA-DRW3. Lancet II:770-771
3. 3. Egido J, Julian BA, Wyatt RJ (1987) Genetic factors in primary IgA nephropathy. Nephrol Dial Transplant 2:134-142
4. 4. Glicklich D, Haskell L, Senitzer D, Weis RA (1988) Possible genetic predisposition to idiopathic focal and segmental glomerulosclerosis. Am J Kidney Dis 12:26-60
5. 5. Mitch WE, Buffington G, Lemaan J, Walser M (1976) Progression of renal failure: a simple method of estimation. Lancet II:1326-1331
6. 6. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounts for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346
7. 7. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644
8. 8. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL (1996) A meta-analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation 94:708-712
9. 9. Staessen JA, Wang JG, Ginocchio G, Petrow V, Saavedra AP, Soubrier F, Vlietinck R, Fagard R (1997) The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 15:1579-1592
10. 10. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM (1998) Association between the angiotensin converting enzyme insertion/deletion polymorphism and diabetic nephropathy: a methodological appraisal and systematic review. J Am Soc Nephrol 9:1653-1663
11. 11. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O (1996) Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50:657-664
12. 12. Jardine AG, Padmanbhan N, Connell JMC (1998) Angiotensin converting enzyme gene polymorphisms and renal disease. Curr Opin Nephrol Hypertens 7:259-264
13. 13. Villard E, Soubrier F (1996) Molecular biology and genetic of the angiotensin-I-converting enzyme gene: potential implications in cardiovascular diseases. Cardiovasc Res 32:999-1007
14. 14. Alhenc-Gelas F, Soubrier F, Hubert C, Allegrini J, Lattion AL, Corvol P (1990) The angiotensin I-converting enzyme (kininase II): progress in molecular and genetic structure. J Cardiovasc Pharmacol 15 [Suppl] 6:25-29
15. 15. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, Clauser E (1991) Expression and characterization of recombinant human angiotensin I converting enzyme. J Biol Chem 266:5540-5546
16. 16. Alhenc-Gelas F, Weare FJ, Johnson RL, Erdös I (1983) Measurement of human converting enzyme level by direct radioimmunoassay. J Lab Clin Med 101:83-96
17. 17. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P (1991) Distribution of plasma angiotensin I-converting enzyme level in healthy men; relationship to environmental and hormonal parameters. J Lab Clin Med 117:33-39
18. 18. Dux S, Aron N, Boner G, Carmel A, Taron A, Rosenfeld JB (1984) Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension. Isr J Med Sci 20:1138-1141
19. 19. Sassano P, Chatellier G, Billaud E, Alhenc-Gelas F, Corvol P, Menard J (1987) Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. A six-month double-blind trial. Am J Med 83:227-235
20. 20. Danser JAH, Schalekamp MADH, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H (1995) Angiotensin-converting-enzyme in the human heart: effect of the insertion/deletion polymorphism. Circulation 92:1387-1388
21. 21. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F (1993) Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 290:33-40
22. 22. Mizuiri S, Yoshikawa H, Tanegashima M, Miyagi M, Kobayshi M, Sakai K, Hayashi I, Aikawa A, Ohara T, Hasegawa A (1998) Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 31:301-307
23. 23. Williams TA, Villard E, Soubrier F (1995) A genetic study of angiotensin I-converting enzyme levels in human semen. Mol Cell Endocrinol 107:215-219
24. 24. Morris BJ, Monaghan JC, Perich R, Stokes GS, Jackson B, Schrader AP (1994) Genotypic influence on plasma dipeptidyl carboxy peptidase-1 activity in hypertensives. Clin Exp Pharmacol Physiol 21:343-346
25. 25. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F (1996) Identification of new polymorphisms of the angiotensin I converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 58:1268-1278
26. 26. Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acid Res 20:1433
27. 27. Ueda S, Heeley RP, Lees KR, Elliiott HL, Connell JMC (1996) Mistyping of the human angiotensin converting enzyme gene polymorphism: frequency, causes and possible methods to avoid typing error. J Mol Endocrinol 17:27-30
28. 28. Fogarty DG, Maxwell AP, Doherty CC, Hughes AE, Nevin NC (1994) ACE gene typing. Lancet 343:851
29. 29. Shanmugam W, Sell KW, Saha BK (1993) Mistyping ACE heterozygotes. PCR Methods Appl 3:120-121
30. 30. Johanning GL, Johnston KE, Tamura T, Goldenberg RL (1995) Ethnic differences in angiotensin gene polymorphism. J Hypertens 13:710-711
31. 31. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffery S, Ogunlesi AO, Sagnella GA (1994) Angiotensin converting enzyme insertion/deletion polymorphism: association with ethnic origin. J Hypertens 12:955-957
32. 32. Bloem LJ, Manatunga AT, Pratt HJ (1996) Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I converting enzyme activity. Hypertension 27:62-66
33. 33. Takahashi K, Nakamura H, Kubota I, Takhashi N, Tomoike H (1995) Association of ACE gene polymorphism with coronary artery disease in a northern area of Japan. Jpn Heart J 36:557-564
34. 34. MacKenzie CA, Julier C, Forrester T, McFarlane-Anderson N, Keavney B, Lathrop GM, Ratcliffe PJ, Farrell M (1995) Segregation and linkage analysis of serum angiotensin-converting enzyme levels: evidence for two quantitative trait loci. Am J Hum Genet 57:1426-1435
35. 35. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TIA, Jensen G, Tybjaerg-Hansen A (1997) ACE gene polymorphism: ischemic heart disease and longevity in 10150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 95:2358-2367
36. 36. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Coehn D (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6:29-30
37. 37. Raij K, Keane WF (1985) Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 79 [Suppl 3C]: 24-30
38. 38. Kagami S, Border WA, Miller DE (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437
39. 39. Wolf G, Neilson EG (1993) Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540
40. 40. McDonald KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parish T, Stillman A, Cohn J (1994) Relative effects of alphal -adrenoreceptor blockade, converting enzyme inhibitor therapy and angiotensin II subtype receptor blockade on ventricular remodeling in the dog. Circulation 90:3034-3046
41. 41. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE (1994) Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 45:177-184
42. 42. Janiak P, Pillon A, Prost J-F, Vilaine J-P (1992) Role of angiotensin subtype 2 receptors in neointima formation after vascular injury. Hypertension 20:737-745
43. 43. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T (1995) The angiotensin II AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651-657
44. 44. Anderson PW, Do YS, Hsueh WA (1993) Angiotensin II causes mesangial cell hypertrophy. Hypertension 21:29-35
45. 45. Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J (1995) Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942
46. 46. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH (1996) The deletion polymorphism of the angiotensin converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 17:787-794
47. 47. Chang PC, Kroon I, van Dijk MA, Danser AH (1998) The role of genetic heterogeneity in angiotensin-converting enzyme in physiological responses to angiotensins and bradykinin in human forearm vascular bed. J Am Soc Nephrol 9:1705A
48. 48. Ueda S, Elliott HL, Morton JJ, Connel JM (1995) Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 25:1266-1269
49. 49. Kleij FGH van der, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D (1997) Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACER-inhibition: role of sodium status. Kidney Int 53:S23-S26
50. 50. Chadwick IG, Kraskiewicz M, Yeo WW, Higgins KS, Jackson PR, Ramsay LE (1996) No relation between angiotensin converting enzyme gene polymorphism and dermal responses to bradykinin in healthy subjects. Clin Sci (Colch) 91:617-620
51. 51. Brown NJ, Blais C, Gandhi SK, Adam A (1998) ACE insertion/deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol 32:373-377
52. 52. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T (1998) Meta-analysis of association of insertion/deletion polymorphism of angiotensin I converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41:47-53
53. 53. Tarnow L, Gluud C, Parving H-H (1998) Diabetic nephropathy and the insertion/deletion polymorphisms of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13: 1125-1130
54. 54. Barnas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, Irsigler K, Mayer G (1997) Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme polymorphism, hypertension and metabolic control. Diabetologia 40:327-331
55. 55. Schmidt S, Schöne N, Ritz E, the diabetic nephropathy study group (1995) Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int 47:1176-1181
56. 56. Marre M, Bouhanick B, Berrut G, Gallois Y, Le Jeune J-J, Chatellier G, Menard J, Alhenc-Gelas F (1999) Renal changes on hyperglycemia and angiotensin converting enzyme in type I diabetes. Hypertension 33:775-778
57. 57. Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe A, Clarckson AR, Ponticelli C, Campise M, Mayer G, Ganten D, Ritz E (1995) No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 26:727-731
58. 58. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rodger RS, Junor BJ, Briggs JD, Connell JMC, Jardine AG (1995) Polymorphism in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345: 1540-1542
59. 59. Hunley TE, Julian BA, Phillips III JA, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V (1996) Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49:571-577
60. 60. Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M (1995) Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 44:80-85
61. 61. Ohmacht C, Kliem V, Burg M, Nashan B, Schlitt H-J, Brunkhorst R, Koch K-M, Floege J (1997) Recurrent Immunoglobulin A nephropathy after renal transplantation. Transplantation 1997:64:1493-1496
62. 62. Perrichot R, Raguenes O, Mercier B, Whebe B, Lenormand JP, Ferec C, Clede J (1996) Genetic variation in the renin-angiotensin system and membranous glomerulonephritis. J Am Soc Nephrol 7:1779A
63. 63. Lee D-Y, Kim W, Kang SK, Koh GY, Park SK (1997) Angiotensin-converting enzyme gene polymorphism in patients with minimal change nephrotic syndrome and focal segmental glomerulosclerosis. Nephron 77:471-473
64. 64. Remuzzi G, Bertani T (1990) Is glomerulosclerosis a consequence of altered permeability to macromolecules? Kidney Int 38:384-394
65. 65. Fernandez-Lama P, Poch E, Oriola J, Botey A, Coll E, Darnell A, Rivera F, Revert L (1998) Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 53:1743-1747
66. 66. Kario K, Kanai N, Nishiuma S, Fujii T, Saito K, Matsuo T, Matsuo M, Shimada K (1997) Hypertensive nephropathy and the gene for angiotensin converting enzyme. Arterioscler Thromb Vasc Biol 17:252-256
67. 67. Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, Bezante GP, Borgia L, Bobola N, Ravazzolo R, Sacchi G, Deferrari G (1996) The deletion polymorphism of the angiotensin converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 7:2550-2558
68. 68. Missouris CG. Barley J. Jeffery S. Carter ND. Singer DRJ. MacGregor GA 1996) Genetic risk for renal artery stenosis: association with deletion polymorphism in angiotensin 1-converting enzyme gene. Kidney Int 49:534-537
69. 69. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R (1996) Patterns of renal injury in type 2 (non-insulin dependent) diabetic patients with micro-albuminuria. Diabetologia 39:1569-1576
70. 70. Parving H-H, Gall M-A, Skøtt P, Jørgensen HE, Lokkegaard H, Jørgensen F, Nielsen B, Larsen S (1992) Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41:758-762
71. 71. McLaughlin KJM, Harden PN, Ueda S, Boulton-Jones JM, Connell JMC, Jardine AG (1996) The role of genetic polymorphisms of angiotensin converting enzyme in the progression of renal diseases. Hypertension 28:912-915
72. 72. Gaciong ZA, Religa P, Placha G, Rell K, Paczek L (1995) Letter. Lancet 346:570
73. 73. Schmidt S, Strojek K, Grzeszczak W, Bergis K Ritz E, the Diabetic Nephropathy Study Group (1997) Excess of DD homozygotes in haemodialysed patients with type II diabetes. Nephrol Dial Transplant 12:427-429
74. 74. Vleming LJ, van der Pijl JW, Lemkes HH, Westendorp RG, Maassen JA, Daha MR, van Es CA, van Kooten C (1999) The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 51:133-140
75. 75. Schmidt A, Kiener HP, Barnas U, Arias I, Illievich A, Auinger M, Graninger W, Kaider A Mayer G (1996) Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. J Am Soc Nephrol 7:314-317
76. 76. Nomura H, Koni I, Michishita Y, Morise T, Takeda R (1994) Angiotensin converting enzyme gene polymorphism in haemodialysis patients. Lancet 343:482-483
77. 77. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O (1995) Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169
78. 78. Parving H-H, Jacobsen P, Tarnow L, Rossing PP, Lecerf L, Poirier O, Cambien F (1996) Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. BMJ 313:591-594
79. 79. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams GD (1997) Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of end stage renal failure in PKD1 adult polycystic kidney disease. Kidney Int 52:607-613
80. 80. Essen GG van, Rensma PL, de Zeeuw D, Sluiter WJ, Apperloo AJ, de Jong PE (1996) Association between angiotensin-converting-enzyme and failure of renoprotective therapy. Lancet 347:94-95
81. 81. Frishberg Y, Becker-Cohen R, Halle D, Feigin E, Eisenstein B, Halevy R, Lotan D, Juabeh I, Ish-Shalom N, Magen D, Shvil Y, Sinai-Treiman L, Drukker A (1998) Genetic polymorphism of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Kidney Int 54:1843-1849
82. 82. Fukushima T, Nomura S, Kawai S, Osawa G (1995) Letter. Lancet 346:571
83. 83. Uemasu J, Nakaoka K, Ishikawa I, Yoshino Y, Shio H, Nemoto R, Nakamura I, Morio S (1997) Lack of association between angiotensin converting enzyme gene polymorphism and clinical features in autosomal dominant polycystic kidney disease. Life Sci 60:2139-2144
84. 84. Burg M, Menne J, Ostendorf T, Kliem V, Floege J (1997) Gene-polymorphisms of angiotensin-converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis. Clin Nephrol 48:205-211
85. 85. Zoccali C, Misefari V, Romeo G, Testa A, Spoto B, Ruggenenti P, Perna A, Matalone M, Remuzzi G (1997) Polymorphism of the angiotensin I converting enzyme (ACE) gene does not predict disease progression, nor response to ACE-inhibition in non-diabetic chronic renal disease. J Am Soc Nephrol 8:0385A
86. 86. Beige J, Schere S, Weber A, Engeli S, Offerman G, Opelz G, Distler A, Sharma AM (1997) Angiotensin converting enzyme genotype and renal allograft survival. J Am Soc Nephrol 8:1319-1323
87. 87. Broekroelofs J, Stegeman CA, Navis GJ, Tegzess AM, de Zeeuw D, de Jong PE (1998) Risk factors for long-term renal survival after renal transplantation: a role for the angiotensin-converting enzyme (insertion/deletion polymorphism? J Am Soc Nephrol 9:2075-2081
88. 88. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D (1997) Association of angiotensinogen gene T235 variant with progression of immunoglobulin A nephropathy in Causcasian patients. J Clin Invest 100:814-820
89. 89. Marre M, Jeunemaitre X, Gallois Y, Rodler M, Chatellier G, Sert C (1997) Contribution of genetic polymorphisms in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. GENEDIAB study group. J Clin Invest 99:1585-1595
90. 90. Navis G, de Zeeuw D, de Jong PE (1997) ACE-inhibitors: panacea for progressive renal disease? Lancet 349:1852-1853
91. 91. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D (1987) Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 32:78-83
92. 92. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P (1996) Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945
93. 93. Lewis EJ, Hunsicker LG, Baim RP, Rohde RD for the collaborative study group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462
94. 94. GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863
95. 95. Gansevoort RT, de Zeeuw D, de Jong PE (1993) Long-term benefits of the antiproteinuric effect of ACE-inhibition in non-diabetic renal disease. Am J Kidney Dis 2:202-206
96. 96. Apperloo AJ, de Zeeuw D, de Jong PE (1994) Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45 [Suppl 45]:174-178
97. 97. Ueda S, Meredith PA, Morton JJ, McConnoll JMC, Elliot HL (1998) ACE (I/D) genotype as a predictor in response of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 98:2148-2153
98. 98. Moriyama T, Kitamara H, Ochi S, Izumi M, Yokoyam K, Yamauchi A, Ueda N, Kamada T, Imai E (1995) Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 6:1674-1678
99. 99. Kitamura H, Moriyama T, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada T, Imai E (1996) Angiotensin I converting enzyme insertion/deletion polymorphism: potential significance in nephrology. Kidney Int 49 [Suppl 55]:S101-S103
100. 100. Kleij FGH van der, Navis G, Gansevoort RT, Heeg JE, Scheffer H, de Zeeuw D, de Jong PE (1997) ACE gene polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol Dial Transplant 12 [Suppl] 2:42-46
101. 101. Vleming LJ, van Kooten C, van Dijk M, Hollander DAMJ, Paape ME, Westendorp RGJ, van Es LA (1999) The D-allele of the ACE gene polymorphism predicts a stronger antiproteinuric response to ACE inhibitors. Nephrology (in press)
102. 102. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner A, Auinger M, Arias I, Schneider B, Mayer G (1998) Angiotensin converting enzyme (ACE) gene polymorphism determines the antiproteinuric and systemic hemodynamic effects of enalapril in patients with proteinuric renal disease. Austrian Study Group of Enalapril in Proteinuric Renal Disease. Kidney Blood Press Res 21:66-69
103. 103. Gonzalo A, Telleria D, San Millan JL, Ortuno J (1998) Angiotensin converting enzyme gene polymorphism and antiproteinuric response to renoprotective therapy. Nephrol Dial Transplant 13:1050-1051
104. 104. Penno G, Chaturvedi N, Talmud PJ, Coroneo P, Manto A, Nannipieri M, Luong l, Fuller JH, the EUCLID study group (1998) Effect of angiotensin converting enzyme (ACE) gene polymorphisms on progression of renal disease and the influence of ACE inhibition in IDDM patients. Diabetes 47:1507-1511
105. 105. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, Cambien F, Parving H-H (1998) Angiotensin-converting enzyme (ACE) gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 53:1002-1006
106. 106. Heeg JE, Jong PE de, Hem GK van der, Zeeuw D de (1989) Efficacy and variability of the antiproteinuric effect of ACE-inhibition by lisinopril. Kidney Int 36:272-279
107. 107. Navis GJ, Jong PE de, Donker AJM, Hem GK van der, Zeeuw D de (1987) Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 31:815-819
108. 108. Kleij FGH van der, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D (1997) ACE I/D polymorphism and short term response to ACE inhibition; role of sodium status. Kidney Int Suppl 63:S23-S26
109. 109. Kawamura T, Yoshida H, Hamaguchi A, Utsunomiya Y, Miyazaki Y, Mitarai I, Ichikawa I, Sakai O (1996) Sodium-dependency of urinary protein excretion is a functional parameter for intrarenal angiotensin and a predictor for long term renoprotective efect of angiotensin converting enzyme inhibition in IgA nephropathy patients. J Am Soc Nephrol 7:1321A
110. 110. Mizuiri S, Hemmi H, Inoue A, Takano M, Kadomatsu S, Tanimotot H, Tanegashima M, Hayashi I, Fushimi T, Hasegawa A (1997) Renal hemodynamic changes induced by captopril and angiotensin converting enzyme gene polymorphism. Nephron 75:310-314
111. 111. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE (1995) Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 39:131-134
112. 112. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JEC, Brown MJ (1995) Renin angiotensin system gene polymorphisms influence blood pressure and response to angiotensin converting enzyme inhibition. J Hypertens 13:1602-1609
113. 113. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P (1996) Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 14:259-262
114. 114. Dieguez-Lucena JL, Aranda-Lara P, Ruiz-Galdón M, Garcia-Villanova J, Morell-Ocana M, Reyes-Engel A (1996) Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension 28:98-103
115. 115. Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318:1657-1666
116. 116. Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000
117. 117. Wapstra FH, Goor H van, Navis GJ, de Jong PE, de Zeeuw D (1996) Short-term antiproteinuric effect of ACE-inhibition predicts renal protection in rats with established adriamycin nephrosis. Clin Sci (Colch) 90:393-400
118. 118. Grond J, Weening J, Elema JD (1984) Glomerular sclerosis in nephrotic rats. Comparison of the long term effects of adriamycin and aminonucleoside. Lab Invest 51:227-285
119. 119. Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, Bezante GP, Borgia L, Bobola N, Ravazzolo R, Sacchi G, Deferrari G (1996) The deletion polymorphism of the angiotensin converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 7:2550-2558
120. 120. Butler R, Morris AD, Burchell B, Struthers AD (1999) DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 33:1164-1168
121. 121. Vaughan DE, Lazos SA, Tong K (1995) Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 95:995-100
122. 122. Eriksson P, Kallin B, van 't Hooft F, Bavenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855
123. 123. Klahr S, Heifets M, Purkerson ML (1986) The influence of anticoagulation on the progression of experimental renal disease. In: Mitch WE, Brenner BM, Stein JH (eds) The progressive nature of renal disease. Contemporary issues in nephrology vol 14. Churchill-Livingstone, New York, pp 45-64
124. 124. Bianchi G, Swales JD (1995) Do we need more anti-hypertensive drugs: lessons from the new biology. Lancet 345: 1555-1557
125. 125. Meerman GJ te, van der Meulen MA, Sandkuil LA (1995) Perspectives of identity by descent (IBD) mapping in founder populations. Clin Exp Allergy 25:97-102